Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) — Stella

Home/Knee Osteoarthritis (Knee OA)/Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

View on ClinicalTrials.gov

Recruiting

Back to Knee Osteoarthritis (Knee OA) trials

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Canada

Sunnybrook Health Sciences Centre, Toronto, Ontario

Key details

Phase

Early testing / Safety & dosing

Sponsor

Dr. David Wasserstein

Collaborators

Sunnybrook Research Institute

Enrollment target

~34 participants

Started

October 2025

Primary completion

July 2028

Age range

18 Years – 65 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.